<DOC>
	<DOCNO>NCT02606136</DOCNO>
	<brief_summary>This Phase 2 , open-label , single arm trial pamrevlumab ( FG-3019 ) estimate pamrevlumab 's safety efficacy non-ambulatory subject DMD .</brief_summary>
	<brief_title>Trial Pamrevlumab ( FG-3019 ) , Non-Ambulatory Subjects With Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>Each subject receive pamrevlumab ( 35 mg/kg ) every two week intravenous infusion least one year . Subjects may continue study additional 6 month ( total year half ) pulmonary function test show stabilization improvement first 52 week treatment FibroGen Medical Monitor approve continue . All subject closely monitor safety . Efficacy assessment perform routinely course study .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>At least 12 year age Written consent/assent patient and/or legal guardian per regional and/or IRB requirement Nonambulatory Brooke Score Arms Shoulders ≤5 Diagnosis DMD medical history confirm Duchenne mutation available genetic test use validate genetic test Able perform spirometry Able undergo cardiac extremity ( upper arm ) MRI Percent predict FVC 40 90 , inclusive At least one historical FVC % predict value within 18 month baseline Left ventricular ejection fraction &gt; 45 % determined cardiac MRI screening within 3 month prior day 0 Subjects currently receive heart failure cardiac medication ( e.g . angiotensin convert enzyme inhibitor , angiotensinreceptor blocker , betablockers ) must achieve stable regimen least 3 month prior screen On stable dose corticosteroid minimum 6 month prior screen substantial change dosage minimum 3 month ( except adjustment change body weight ) prior screen foreseen change corticosteroid use course study participation Received pneumococcal vaccine receive annual influenza vaccination Adequate renal function : cystatin C ≤1.4 mg/L Adequate hematological function 1 . Platelets &gt; 100,000/mcL 2 . Hemoglobin &gt; 12 g/dL 3 . Absolute neutrophil count &gt; 1500/μL Adequate hepatic function 1 . No history evidence liver disease 2 . Gamma glutamyl transferase ( GGT ) ≤3 x upper limit normal ( ULN ) 3 . Total bilirubin ≤1.5xULN If sexually active , use medically accepted contraceptive participation study 3 month last dose study drug Requires ≥16 hour continuous ventilation Prior ongoing medical condition , investigator 's opinion , could adversely affect safety subject , make unlikely course 78 week treatment followup would complete , could impair assessment study result Anticipated spine surgery within 78 week Severe uncontrolled heart disease 1 . Need intravenous diuretic inotropic support within 3 month prior screen 2 . Hospitalization heart failure exacerbation arrhythmia last 3 month Arrhythmia require antiarrhythmic therapy Hospitalization due respiratory failure last 6 week Poorly control asthma underlying lung disease bronchopulmonary dysplasia Known suspect active hepatitis B C history HIV BMI ≥40 kg/m^2 weight &gt; 117 kg Exposure another investigational drug within 28 day prior start study treatment Exposure another investigational drug another approve product DMD ( e.g . eteplirsen ) within 28 day prior start study treatment ( 5 halflives product whichever longer ) prior first screen visit exception deflazacort . Use deflazacort regard principal investigator standard care allow .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Duchenne</keyword>
	<keyword>muscular</keyword>
	<keyword>dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>non-ambulatory</keyword>
</DOC>